ARQL - ArQule: Still Has Room To Run In 2019
Today, we want to share our analysis of ArQule (ARQL) with you. The company's stock price has declined by over 20% since July despite the absence of company-specific negative news. However, the company has a number of bullish signs including an adequate balance sheet, large institutional ownership, as well as strong pipeline progress. So, let's dig in!
Company description
ArQule is a clinical-stage biotechnology company focused on the development of therapeutics for the treatment of cancer and rare diseases. The company, based in Burlington, Massachusetts, was founded in 1993 and went public in October